Innovent Biologics (OTCMKTS:IVBXF) Shares Cross Above 200-Day Moving Average – Should You Sell?

Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $11.22 and traded as high as $11.24. Innovent Biologics shares last traded at $11.24, with a volume of 1,139 shares traded.

Innovent Biologics Stock Performance

The business has a 50-day moving average of $11.95 and a two-hundred day moving average of $11.22.

Innovent Biologics Company Profile

(Get Free Report)

Innovent Biologics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. The company primarily targets oncology, autoimmune, cardiovascular and metabolic diseases, with an emphasis on biologic therapies, biosimilars and other specialty treatments. Its marketed and development portfolio includes therapies such as TYVYT (sintilimab), a PD-1 inhibitor developed in collaboration with Eli Lilly, as well as products based on or related to bevacizumab, rituximab and adalimumab.

Featured Stories

Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.